You are here

The Development of TLR Antagonists for Therapy of Hepatic Fibrosis and Cirrhosis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA176892-01A1
Agency Tracking Number: R43CA176892
Amount: $143,649.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
10054 Mesa Ridge CT, Suite 114
SAN DIEGO, CA 92121-2964
United States
DUNS: 78518178
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 GUIXIN SHI
 (858) 312-6036
 guixinshi@gmail.com
Business Contact
 MIN YIN
Phone: (858) 312-6036
Email: minjeanyin01@yahoo.com
Research Institution
 Stub
Abstract

Abstract There is an unmet need for cost-efficient technologies for high purity isolation of rare circulating tumor cells (CTCs) from blood. An ideal isolation technique should be able to meet the following criteria: (a) minimal processing time; (b) low final sample volume; (c) isolation from large blood volume; (d) low carryover of leukocytes and blood components; (e) high cell viability; (f) compatibility with downstream processes such as PCR or tissue culturing; (g) low cost and ease of operation by entry-level personnel. While there are numerous approaches for CTC isolation, none of them combines simplicity, low cost, efficiency and speed. Previously, we developed a novel process of buoyant microbubble-assisted isolation of rare tumor cells from blood and buffy coats. MBs efficiently (gt80% recovery) and fast (less than 20 min) isolated rare tumor cells from 7 ml blood or 22 ml buffy coats. For Phase I, Diagnologix, LLC has partnered with the University of California San Diego in order to develop and testa prototype of an intuitive and user-friendly separation/harvesting device that in combination with MBs will be used for harvesting rare tumor cells from complex biological fluids (e.g., blood). The proposed setup will enable easy washing, immunostaining,genetic analysis or culturing of isolated CTCs. The most important competitive advantages of MB approach vs. magnetic beads would be high speed, sample purity, simplicity, flexibility, minimal final sample volume and low cost. The value proposition of thetechnology is in the qualitative and quantitative improvement in CTC isolation and analysis for biomedical and clinical research and potentially for clinical diagnostics. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The proposal aims to develop a simple to operate and inexpensive device for isolation of rare cell types from blood and other biological fluids. This technology has the potential to improve cancer diagnostics in general population.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government